Nerve-Zapping procedure could boost liver cancer therapy

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged 18 to 75 years (inclusive), regardless of gender. 2. Diagnosis of CNLC Stage IIIa HCC with portal vein tumor thrombus (vp type 1-3) confirmed by histopathology, cytology, or imaging. 3. Progression of disease after first-line systemic therapy. 4. At least one measurable lesion according to RECIST 1.1 criteria. 5. Child-Pugh class A or B. 6. ECOG performance status of 0 to 2. 7. Scheduled to undergo TACE or HAIC treatment. 8. Adequate hematological, hepatic, and renal function within 14 days prior to study initiation, defined as: White blood cell count ≥2.0×10⁹/L AND neutrophil count ≥1.0×10⁹/L. Platelet count ≥60×10⁹/L. Hemoglobin concentration ≥90 g/L. Total bilirubin ≤2.0 × upper limit of normal (ULN). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤5 × ULN. Albumin ≥2.8 g/dL. International normalized ratio (INR) ≤1.6. Creatinine ≤1.5 × ULN AND calculated creatinine clearance ≥30 mL/min. Exclusion Criteria: 1. Preoperative abdominal CT or MR enhanced scan suggests celiac trunk anatomy is unsuitable for EDN procedure. 2. History of orthostatic hypotension. 3. Diffuse liver tumors or extensive extrahepatic metastases with an expected survival of \<3 months. 4. Cachexia or multi-organ failure. 5. Severe hepatic dysfunction (Child-Pugh class C). 6. Uncorrectable coagulation dysfunction. 7. Presence of severe concurrent infection. 8. Accompanied by Vp4 type portal vein tumor thrombus. 9. Abnormal blood supply to the target lesion that precludes transarterial interventional therapy. 10. History of bilioenteric anastomosis within the past year. 11. Severe allergy to known contrast agents or embolization materials. 12. Pregnant or lactating women, or individuals with childbearing potential planning pregnancy during the trial period. 13. Clinically significant (e.g., active) cardiovascular disease, including: Unstable angina within ≤6 months prior to randomization. New York Heart Association (NYHA) class ≥II congestive heart failure. Poorly controlled arrhythmia despite medication (patients with controlled atrial fibrillation are eligible), or any clinically significant abnormality found on resting ECG. ≥Grade 3 peripheral vascular disease (e.g., symptomatic and interfering with activities of daily living, requiring intervention). Transient ischemic attack or subarachnoid hemorrhage within 6 months prior to randomization, or participation in other drug or device clinical trials within 3 months. 14. History of other malignancies within the past 5 years or concurrent other malignancies. 15. Any other condition deemed by the investigator as unsuitable for participation in this study.